{"id":46967,"date":"2022-08-04T23:01:57","date_gmt":"2022-08-04T21:01:57","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/vapotherm-to-participate-in-the-canaccord-genuity-42nd-annual-growth-conference\/"},"modified":"2022-08-04T23:01:57","modified_gmt":"2022-08-04T21:01:57","slug":"vapotherm-to-participate-in-the-canaccord-genuity-42nd-annual-growth-conference","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/vapotherm-to-participate-in-the-canaccord-genuity-42nd-annual-growth-conference\/","title":{"rendered":"Vapotherm to Participate in the Canaccord Genuity 42nd Annual Growth Conference"},"content":{"rendered":"
\n

EXETER, N.H.–(BUSINESS WIRE)–Vapotherm, Inc. (NYSE: VAPO), (\u201cVapotherm\u201d or the \u201cCompany\u201d), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy\u00ae products, which are used to treat patients of all ages suffering from respiratory distress, today announced that its management team will be participating in the Canaccord Genuity 42nd<\/sup> Annual Growth Conference on Thursday, August 11, 2022 via webcast.\n<\/p>\n

<\/a><\/p>\n

\nVapotherm is scheduled to present at 11:00 am Eastern Time. The presentation will be accessible via a live webcast at https:\/\/wsw.com\/webcast\/canaccord76\/vapo\/2472498<\/a>.\n<\/p>\n

\nA webcast replay of the presentation will be available for 90 days following the presentation in the Event Archive section of Vapotherm\u2019s Investor website at http:\/\/investors.vapotherm.com\/<\/a>.\n<\/p>\n

\nAbout Vapotherm<\/b>\n<\/p>\n

\nVapotherm, Inc. (NYSE: VAPO) is a publicly traded developer and manufacturer of advanced respiratory technology based in Exeter, New Hampshire, USA. The Company develops innovative, comfortable, non-invasive technologies for respiratory support of patients with chronic or acute breathing disorders. Over 3.5 million patients have been treated with the use of Vapotherm high velocity therapy\u00ae systems. For more information, visit www.vapotherm.com<\/a>.\n<\/p>\n

\nVapotherm high velocity therapy is mask-free noninvasive ventilatory support and is a front-line tool for relieving respiratory distress\u2014including hypercapnia, hypoxemia, and dyspnea. It allows for the fast, safe treatment of undifferentiated respiratory distress with one tool. The Precision Flow system\u2019s mask-free interface delivers optimally conditioned breathing gases, making it comfortable for patients and reducing the risks and care complexities associated with mask therapies. While being treated, patients can talk, eat, drink and take oral medication.\n<\/p>\n

\nWebsite Information<\/b>\n<\/p>\n

\nVapotherm routinely posts important information for investors on the Investor Relations section of its website, http:\/\/investors.vapotherm.com\/<\/a>. Vapotherm intends to use this website as a means of disclosing material, non-public information and for complying with Vapotherm\u2019s disclosure obligations under Regulation FD. Accordingly, investors should monitor the Investor Relations section of Vapotherm\u2019s website, in addition to following Vapotherm\u2019s press releases, Securities and Exchange Commission filings, public conference calls, presentations and webcasts. The information contained on, or that may be accessed through, Vapotherm\u2019s website is not incorporated by reference into, and is not a part of, this document.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nInvestor Relations:<\/b>
Mark Klausner or Mike Vallie, Westwicke, an ICR Company, ir@vtherm.com<\/a>, +1 (603) 658-0011\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

EXETER, N.H.–(BUSINESS WIRE)–Vapotherm, Inc. (NYSE: VAPO), (\u201cVapotherm\u201d or the \u201cCompany\u201d), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy\u00ae products, which are used to treat patients of all ages suffering from respiratory distress, today announced that its management team will be participating in the Canaccord Genuity … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-46967","6":"format-standard","7":"category-industry"},"yoast_head":"\nVapotherm to Participate in the Canaccord Genuity 42nd Annual Growth Conference - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/vapotherm-to-participate-in-the-canaccord-genuity-42nd-annual-growth-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Vapotherm to Participate in the Canaccord Genuity 42nd Annual Growth Conference - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"EXETER, N.H.–(BUSINESS WIRE)–Vapotherm, Inc. (NYSE: VAPO), (\u201cVapotherm\u201d or the \u201cCompany\u201d), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy\u00ae products, which are used to treat patients of all ages suffering from respiratory distress, today announced that its management team will be participating in the Canaccord Genuity ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/vapotherm-to-participate-in-the-canaccord-genuity-42nd-annual-growth-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-08-04T21:01:57+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220804005742\/en\/1535380\/21\/VAPO_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/vapotherm-to-participate-in-the-canaccord-genuity-42nd-annual-growth-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/vapotherm-to-participate-in-the-canaccord-genuity-42nd-annual-growth-conference\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Vapotherm to Participate in the Canaccord Genuity 42nd Annual Growth Conference\",\"datePublished\":\"2022-08-04T21:01:57+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/vapotherm-to-participate-in-the-canaccord-genuity-42nd-annual-growth-conference\\\/\"},\"wordCount\":393,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/vapotherm-to-participate-in-the-canaccord-genuity-42nd-annual-growth-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220804005742\\\/en\\\/1535380\\\/21\\\/VAPO_Logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/vapotherm-to-participate-in-the-canaccord-genuity-42nd-annual-growth-conference\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/vapotherm-to-participate-in-the-canaccord-genuity-42nd-annual-growth-conference\\\/\",\"name\":\"Vapotherm to Participate in the Canaccord Genuity 42nd Annual Growth Conference - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/vapotherm-to-participate-in-the-canaccord-genuity-42nd-annual-growth-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/vapotherm-to-participate-in-the-canaccord-genuity-42nd-annual-growth-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220804005742\\\/en\\\/1535380\\\/21\\\/VAPO_Logo.jpg\",\"datePublished\":\"2022-08-04T21:01:57+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/vapotherm-to-participate-in-the-canaccord-genuity-42nd-annual-growth-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/vapotherm-to-participate-in-the-canaccord-genuity-42nd-annual-growth-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/vapotherm-to-participate-in-the-canaccord-genuity-42nd-annual-growth-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220804005742\\\/en\\\/1535380\\\/21\\\/VAPO_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220804005742\\\/en\\\/1535380\\\/21\\\/VAPO_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/vapotherm-to-participate-in-the-canaccord-genuity-42nd-annual-growth-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Vapotherm to Participate in the Canaccord Genuity 42nd Annual Growth Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Vapotherm to Participate in the Canaccord Genuity 42nd Annual Growth Conference - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/vapotherm-to-participate-in-the-canaccord-genuity-42nd-annual-growth-conference\/","og_locale":"en_US","og_type":"article","og_title":"Vapotherm to Participate in the Canaccord Genuity 42nd Annual Growth Conference - Pharma Trend","og_description":"EXETER, N.H.–(BUSINESS WIRE)–Vapotherm, Inc. (NYSE: VAPO), (\u201cVapotherm\u201d or the \u201cCompany\u201d), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy\u00ae products, which are used to treat patients of all ages suffering from respiratory distress, today announced that its management team will be participating in the Canaccord Genuity ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/vapotherm-to-participate-in-the-canaccord-genuity-42nd-annual-growth-conference\/","og_site_name":"Pharma Trend","article_published_time":"2022-08-04T21:01:57+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220804005742\/en\/1535380\/21\/VAPO_Logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/vapotherm-to-participate-in-the-canaccord-genuity-42nd-annual-growth-conference\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/vapotherm-to-participate-in-the-canaccord-genuity-42nd-annual-growth-conference\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Vapotherm to Participate in the Canaccord Genuity 42nd Annual Growth Conference","datePublished":"2022-08-04T21:01:57+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/vapotherm-to-participate-in-the-canaccord-genuity-42nd-annual-growth-conference\/"},"wordCount":393,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/vapotherm-to-participate-in-the-canaccord-genuity-42nd-annual-growth-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220804005742\/en\/1535380\/21\/VAPO_Logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/vapotherm-to-participate-in-the-canaccord-genuity-42nd-annual-growth-conference\/","url":"https:\/\/pharma-trend.com\/en\/vapotherm-to-participate-in-the-canaccord-genuity-42nd-annual-growth-conference\/","name":"Vapotherm to Participate in the Canaccord Genuity 42nd Annual Growth Conference - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/vapotherm-to-participate-in-the-canaccord-genuity-42nd-annual-growth-conference\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/vapotherm-to-participate-in-the-canaccord-genuity-42nd-annual-growth-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220804005742\/en\/1535380\/21\/VAPO_Logo.jpg","datePublished":"2022-08-04T21:01:57+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/vapotherm-to-participate-in-the-canaccord-genuity-42nd-annual-growth-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/vapotherm-to-participate-in-the-canaccord-genuity-42nd-annual-growth-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/vapotherm-to-participate-in-the-canaccord-genuity-42nd-annual-growth-conference\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220804005742\/en\/1535380\/21\/VAPO_Logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220804005742\/en\/1535380\/21\/VAPO_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/vapotherm-to-participate-in-the-canaccord-genuity-42nd-annual-growth-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Vapotherm to Participate in the Canaccord Genuity 42nd Annual Growth Conference"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46967","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=46967"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46967\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=46967"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=46967"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=46967"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}